Introduction to Dyslipidemia

  • Revised lecture focusing on acquired and inherited lipid disorders.
  • Disclaimer that this lecture aims at foundations rather than comprehensive coverage of every lipid disorder.
  • Objectives:
    • Recognize causes and impacts of acquired and inherited disorders.
    • Discuss treatment strategies for management.

Characterization of Hyperlipidemia

  • Definition of hyperlipidemia: simply stating "lipids are high" lacks specificity.
  • Strategies to characterize hyperlipidemia:
    • Analyze lipid levels (e.g., cholesterol vs. triglycerides).
    • Identify lipoprotein phenotypes (e.g., elevated VLDL, LDL, chylomicrons, HDL).
  • Importance of recognizing patterns in human physiology:
    • Correlating specific conditions with expected outcomes.
    • Role of genotypes in patient outcomes.

Classification of Lipoproteins

  • Friedrichsen-Levy Classification Scheme:
    • Structured by Roman numerals, reflecting various lipoprotein patterns.
  • Lipoprotein Types:
    • Type I: Chylomicronemia only.
    • Type II: High LDL cholesterol.
    • Type IIa: Pure high LDL.
    • Type IIb: High LDL + VLDL.
    • Type III: Remnant disease (abnormal IDL).
    • Type IV: High VLDL without chylomicrons.
    • Type V: Chylomicronemia + high VLDL.

Diagnostic and Clinical Considerations

  • Recognition of lipid emergencies:
    • Total cholesterol >500 mg/dL warrants immediate attention.
    • Triglycerides >2000 mg/dL considered an emergency.
  • Distinction between mild and severe cases and their implications.

Causes of Low HDL Cholesterol

  • Common causes:
    • Elevated triglycerides, visceral obesity, type two diabetes.
  • Dietary impacts:
    • The effects of low fat or high sugar diets.
    • Vegan diets often show low HDL and high triglycerides.
  • Medications that lower HDL:
    • Beta-blockers, fibrates, etc.

Genetic Influences on Lipid Disorders

  • Monogenic vs. Polygenic:
    • Monogenic disorders result from single gene mutations (e.g., familial hypercholesterolemia).
    • Polygenic disorders arise from multiple gene variants affecting lipid levels.
  • Genetic counseling and testing play a crucial role in managing these disorders.

Focus on Familial Hypercholesterolemia (FH)

  • FH Overview:
    • Autosomal codominant condition with high LDL levels.
    • Associated with premature atherosclerotic disease.
    • Diagnosis requires clinical criteria and may now incorporate genetic testing (ICD-10 codes).
    • Common physical stigmata are decreasing in prevalence due to earlier treatment.
  • Physiological Mechanism:
    • Involves dysfunction in LDL particle clearance (LDL receptor and ApoB interactions).
  • Prevalence of FH:
    • More common than previously acknowledged; prevalence of ~1 in 300 individuals.

Genetic Testing Recommendations

  • Dutch Lipid Clinic Network useful for establishing FH diagnoses based on clinical examination data.
  • New approaches involve genetic testing to categorize patients.
  • Phenotype assessment informs genotype sequencing recommendations.

Secondary Causes of Dyslipidemia

  • To be aware of potential secondary causes including:
    • Diet, medications, metabolic disorders (e.g., hypothyroidism, diabetes).
    • Weight changes: rapid loss or gain directly influence lipoprotein levels.

Lipoprotein(a) [Lp(a)]

  • Overview of its role as an independent risk factor for cardiovascular disease.
  • Highly genetically determined with little environmental influence.
  • Apolipoprotein(a) structure (Kringle IV subtype)** and its polymorphisms.
  • Implication of Lp(a) levels on atherosclerotic risk.

Chylomicronemia

  • Triglycerides and their risks:
    • Understanding the triglyceride distribution relevant to patient assessments.
    • Levels >150 mg/dL indicate increased risk for both atherosclerotic cardiovascular disease and pancreatitis.
  • Clinical implications:
    • Acute pancreatitis risk increases with triglyceride levels; importance of rapid management strategies.
    • Summary of specific causes for chylomicronemia and differentiation between Familial Chylomicronemia Syndrome (FCS) and multifactorial conditions.

Treatment Strategies

  • Emphasis on lifestyle modification as first-line treatment before medications.
  • Different medications for various lipid disorders including statins, PCSK9 inhibitors, etc.
  • Acknowledge challenges in treatment efficacy based on underlying genetic conditions.

Conclusions and Implications of Learning

  • Understand the importance of characterizing dyslipidemia thoroughly.
  • Engage in genetic testing and family assessments for conditions like FH.
  • Further exploration of new pharmacotherapies and treatment guidelines is ongoing.